ValuEngine upgraded shares of Stryker Corporation (NYSE:SYK) from a hold rating to a buy rating in a research report report published on Tuesday.
A number of other analysts have also recently weighed in on SYK. Royal Bank Of Canada reaffirmed a buy rating and issued a $155.00 price objective on shares of Stryker Corporation in a report on Monday, October 2nd. BidaskClub raised shares of Stryker Corporation from a hold rating to a buy rating in a report on Thursday, August 17th. SunTrust Banks, Inc. reaffirmed a buy rating and issued a $161.00 price objective on shares of Stryker Corporation in a report on Monday, October 2nd. Oppenheimer Holdings, Inc. set a $156.00 price objective on shares of Stryker Corporation and gave the stock a hold rating in a report on Monday, October 30th. Finally, Cowen and Company reaffirmed a buy rating and issued a $160.00 price objective (up previously from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of $152.10.
Shares of Stryker Corporation (NYSE SYK) opened at $155.40 on Tuesday. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. Stryker Corporation has a twelve month low of $108.29 and a twelve month high of $160.62. The firm has a market cap of $58,560.00, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 2.46 and a beta of 0.79.
Stryker Corporation (NYSE:SYK) last released its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.02. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The business had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter last year, the company earned $1.39 EPS. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. sell-side analysts anticipate that Stryker Corporation will post 6.47 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by BBNS and is the sole property of of BBNS. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/stryker-corporation-syk-raised-to-buy-at-valuengine/1782840.html.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the transaction, the insider now owns 83,207 shares in the company, valued at approximately $12,925,375.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 7.40% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Acrospire Investment Management LLC acquired a new position in shares of Stryker Corporation in the second quarter worth about $111,000. Motco boosted its holdings in shares of Stryker Corporation by 50.7% in the second quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after buying an additional 278 shares during the period. Bollard Group LLC boosted its holdings in shares of Stryker Corporation by 0.4% in the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after buying an additional 3 shares during the period. San Francisco Sentry Investment Group CA boosted its holdings in shares of Stryker Corporation by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after buying an additional 325 shares during the period. Finally, Bruderman Asset Management LLC acquired a new position in shares of Stryker Corporation in the second quarter worth about $150,000. Institutional investors own 74.15% of the company’s stock.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with our FREE daily email newsletter.